GLP-1s & Health Conditions

The foundational use case: HbA1c reduced 1.5-2.0%, cardiovascular death cut 26% (SUSTAIN 6), 10-15% weight loss. ADA guidelines now recommend GLP-1s as first-line with CV disease.

SELECT trial: 20% reduction in major cardiovascular events. FDA-approved for CV risk reduction (March 2024). First weight-loss drug ever approved for heart disease.

Zepbound: first FDA-approved drug for obstructive sleep apnea (Dec 2024). Only 4% needed CPAP vs 22% without. 26% of CPAP users stopped it.

FDA-approved for MASH with liver fibrosis (Aug 2025). Reduces hepatic fat, inflammation, and fibrosis progression. ~25% of Americans have NAFLD.

FDA-approved for diabetic CKD. FLOW trial: semaglutide slowed progression to dialysis. Reduces glomerular inflammation and oxidative stress.

SURMOUNT-1: tirzepatide reduced diabetes progression ~94%. In STEP trials, 84% reverted to normal blood sugar. The strongest evidence in the entire GLP-1 catalog.

GLP-1s improve HOMA-IR by 30-50%. The upstream driver of prediabetes, PCOS, fatty liver, and hypertension. Standard glucose tests miss it for years.

Tirzepatide lowers systolic BP 7-8 mmHg. Semaglutide 3-6 mmHg. Every 5 mmHg cut reduces CV event risk ~10%. Complements but doesn't replace BP meds.

Triglycerides down 15-20%, CRP down ~40%. Targets the atherogenic dyslipidemia pattern that statins miss. Complementary, not a replacement.

Obesity doubles to triples gout risk. GLP-1 users show fewer flares in 2024-2025 cohort studies. Caution: rapid early weight loss can trigger temporary flares.

86% showed nerve improvement within 1 month in a 2024 Diabetologia study. 32% returned to normal nerve morphology. Potential breakthrough for diabetic nerve damage.

SUSTAIN 6: 39% reduction in non-fatal stroke. SELECT: 7% fewer strokes with semaglutide in obesity. GLP-1s address multiple stroke risk factors simultaneously.

41.7-point pain score reduction in knee OA. Weight relief + direct anti-inflammatory effects — GLP-1 receptors confirmed in joint tissue (2026).

Jorge et al. 2026: 34% fewer CV events, 74% lower mortality. Safe with immunosuppressants. Helps prednisone weight gain.

Reduces TNF-alpha and modulates IL-17 pathways. Improved PASI scores. Works alongside biologics with no known interactions.

Fewer hospitalizations, no increased flare signal. GLP-1 and GLP-2 are sister hormones. Best for stable remission, BMI 27+.

14-18% lower respiratory disease risk. GLP-1 receptors in lung tissue. GATA-3 trial underway for symptomatic asthma.

Lancet Psychiatry 2026: lower risk of worsening mental illness. GLP-1 receptors in the brain may have neuroprotective effects. FDA safety warnings exist.

40-70% lower Alzheimer's risk in observational studies — but Phase 3 trials failed for existing disease. The story is prevention, not treatment.

Migraine days cut nearly in half (20→11/month) in a pilot study — results were independent of weight loss. CGRP pathway connection.

Lancet 2026 RCT: semaglutide significantly reduces heavy drinking days. VA study of 600K+ patients suggests GLP-1s may fight addiction broadly.

40-60% lower risk in observational studies. GLP-1 receptors on dopamine neurons in the substantia nigra. Exenatide trials show motor benefits. Larger semaglutide trials underway.

GLP-1s suppress food-reward dopamine signaling — binge episodes reduced 40-70%. The first treatment approach that addresses the neurological roots of binge eating.

Semaglutide + metformin restored regular menstrual cycles in ~12 weeks (2025 RCT). Breaks the insulin-androgen cycle. Fertility warning included.

HRT + GLP-1 synergy: 16% body weight loss. Women 50-64 are the highest GLP-1 user demographic. Bone density considerations.

GLP-1s restore ovulation in women with PCOS and obesity — leading to unexpected pregnancies. Stop semaglutide 2+ months before conception.

~40% report improved satisfaction, ~15% report worsening during titration. Net positive long-term. PT-141 and tadalafil options covered.

July 2026 UC San Diego study: semaglutide reduced biological aging speed by 9% and lowered biological age by 3.1 years. Honest caveats included.

17-41% lower cancer risk across multiple 2025-2026 studies. 30% lower breast, 58% lower endometrial. Outperformed equivalent weight loss from diet/exercise.

No fracture increase in SELECT trial (17,604 patients). GLP-1 receptors on bone-forming cells. GLP-1s preserve bone better than equivalent weight loss from surgery.

Oak, Gala, ShedRx, YourEra — compounded semaglutide and tirzepatide from $99/mo, no insurance needed